8 Best Genomics Stocks to Buy According to Analysts
On June 8, 2026, Google DeepMind, Google.org, and the Wellcome Sanger Institute announced a five-year artificial intelligence collaboration for genomics.
Beam Therapeutics Inc. (BEAM)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | ARK Investment Management Catherine D. Wood | 12,133,433 | $289,139,697 | -3% | 2.25% |
| 2. | Farallon Capital Thomas Steyer | 10,134,696 | $241,509,806 | +1% | 1.38% |
| 3. | Kynam Capital Derrick Tang | 3,682,185 | $87,746,469 | +51% | 5.41% |
| 4. | ADAR1 Capital Management Daniel Schneeberger | 1,446,375 | $34,467,116 | 2.03% | |
| 5. | Casdin Capital Eli Casdin | 1,350,000 | $32,170,500 | -16% | 2.44% |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $34.73 | 373 | $12,954.29 | 102,363 | 2026-06-30 | Filing | |
| $34.84 | 1,900 | $66,203.03 | 1,047,205 | 2026-06-30 | Filing | |
| $34.26 | 23,100 | $791,482.23 | 1,049,105 | 2026-06-30 | Filing | |
| $35.91 | 11,579 | $415,823.89 | 1,047,205 | 2026-06-29 | Filing | |
| $35.13 | 13,421 | $471,528.05 | 1,058,784 | 2026-06-29 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 554 | $19,013 | 0% | |
| 2. | 5 | $172 | 0% |
News See All
10 Best Gene Therapy Stocks to Buy in 2026
Gene therapies aim to treat or prevent diseases by introducing new instructions in a patient’s cells to fix or replace the defective genes behind genetic disorders.
Is Beam Therapeutics Inc. (BEAM) A Good Stock To Buy Now?
Is BEAM a good stock to buy? We came across a bullish thesis on Beam Therapeutics Inc. on r/ValueInvesting by Significant-Pair-275.
14 Stocks on Jim Cramer’s Radar: Nokia, Cameco, and AI Stocks’ Dip
In this article, we will look at the stocks on Jim Cramer’s Mad Money radar as he discussed the recent sell-off in AI-related stocks.
10 Best Biotech Stocks with Highest Upside Potential
On April 16, reports from J.P. Morgan's biopharma and medtech venture and licensing studies indicated that the capital markets began the year 2026 with selective strength.
10 Stocks That Could 10X Over the Next 5 Years
March appears to be finishing on a low note, with the S&P 500 dipping on March 30, pulled down by new rises in oil prices and a sharp decline in technology, as traders moved on from Fed Chair Jerome Powell...
RBC Capital Maintains a Sector Perform Rating on Beam Therapeutics (BEAM), Here's Why
Beam Therapeutics Inc. (NASDAQ:BEAM) is one of the top gene therapy stocks to buy according to hedge funds. On February 25, RBC Capital adjusted the price target on Beam Therapeutics Inc.
Top 10 Gene Therapy Stocks to Buy According to Hedge Funds
On February 23, Lauren Goodwin, New York Life Investments, appeared on CNBC’s ‘Closing Bell’ to talk about the state of equity markets and tariff uncertainties.
Beam Therapeutics Inc. (NASDAQ:BEAM) Q4 2025 Earnings Call Transcript
Operator: Good morning, and welcome to Beam Therapeutics Conference Call. [Operator Instructions] Please be advised that this call is being recorded at Beam's request.
Analyst Bullish on Beam Therapeutics (BEAM) Over Drug Program Trajectory
Beam Therapeutics Inc. (NASDAQ:BEAM) is one of the 13 hot stocks to buy with the highest upside potential. On February 9, Sami Corwin from William Blair maintained a Buy rating on Beam Therapeutics.
Hedge Fund Resource Center